Back to News
Market Impact: 0.2
Two Independent Research Teams Converge on Novel Immune Checkpoint PLA2G2D as a Path to Overcome Anti-PD-1 Resistance in Cancer
Source: PR Newswire
Healthcare & BiotechTechnology & InnovationProduct LaunchesCorporate Guidance & Outlook
Apeximmune said a Nature publication validated its novel PLA2G2D target and identified an enzyme-independent mechanism previously overlooked by the field. The company’s first-in-class anti-PLA2G2D antibody, AI-306, is progressing toward an IND filing in Q2 2027. The publication provides scientific validation, but the program remains preclinical and years from potential commercialization.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economist
- How Pepsi fell behind in the cola wars—and then lost KFC
- 5 big analyst AI moves: ’Uniquely catalyst-rich’ months ahead for SpaceX
- Xencor reports phase 1 data for cancer drug XmAb819
- The experience economy keeps defying expectations. Maybe we’ve been looking at it all wrong
- The U.S. military and NASA have power problems. Nuclear microreactors might solve both